IP Library Granted Patent US 11,655,255
Granted Patent B2
US 11,655,255 · App. 17/967,117 · Granted May 23, 2023

Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein

Inventors: Wanbin Zhang (Shanghai, CN); Mo Wang (Shanghai, CN); Lu Zhang (Shanghai, CN); Xiaohong Huo (Shanghai, CN); Zhenfeng Zhang (Shanghai, CN); Qianjia Yuan (Shanghai, CN); Jianzhong Chen (Shanghai, CN)
Assignees: SPH NO.1 BIOCHEMICAL & PHARMACEUTICAL CO., LTD.; Shanghai Jiaotong University
C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,655,255
App. No.
17/967,117
Granted
May 23, 2023
Kind
B2
Abstract

A method for catalytic asymmetric synthesis of a phosphorus-stereogenic (P-stereogenic) nucleoside derivative of formula (3) and a catalyst used therein. The P-stereogenic nucleoside derivative (3) can be hydrolyzed to obtain remdesivir. Specifically, a nucleoside and phosphoryl chloride are subjected to asymmetric reaction under the catalysis of a chiral bicyclic imidazole catalyst in the presence of a base to produce the P-stereogenic nucleoside derivative of formula (3)

Claims (9)

1. A method for preparing a phosphorus-stereogenic (P-stereogenic) nucleoside derivative of formula (3), comprising:

subjecting a nucleoside and phosphoryl chloride to asymmetric reaction in a solvent under the catalysis of a chiral bicyclic imidazole catalyst in the presence of a base to obtain the P-stereogenic nucleoside derivative of formula (3):

wherein the base is an inorganic base, and the inorganic base is selected from the group consisting of sodium carbonate, potassium carbonate, cesium carbonate, disodium hydrogen phosphate, sodium bicarbonate and potassium bicarbonate.

2. The method of claim 1 , wherein the chiral bicyclic imidazole catalyst is selected from the group consisting of:

3. The method of claim 2 , wherein C1-C18 are all in S configuration.

4. The method of claim 1 , wherein the solvent is selected from the group consisting of methylbenzene, diethyl ether, 1,3-dioxolane, 1,4-dioxane, tetrahydrofuran, dichloromethane, trichloromethane, 1,2-dichloroethane, ethyl acetate, acetone, acetonitrile and a combination thereof.

5. The method of claim 1 , wherein a molar ratio of the chiral bicyclic imidazole catalyst to the nucleoside is 1:(5˜100).

6. The method of claim 1 , wherein a molar ratio of the nucleoside to the phosphoryl chloride is 1:(0.5˜3.0); and a molar ratio of the nucleoside to the base is 1:(1.0˜4.0).

7. The method of claim 1 , wherein the asymmetric reaction is performed at −100˜80° C. for 1-72 h.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2023
From: ZHANG, WANBIN; WANG, MO; ZHANG, LU; HUO, XIAOHONG; ZHANG, ZHENFENG; YUAN, QIANJIA; CHEN, JIANZHONG
To: SPH NO.1 BIOCHEMICAL & PHARMACEUTICAL CO.,LTD.; SHANGHAI JIAOTONG UNIVERSITY
Reel/Frame 063293/0656 →
Continuity (1)
Related Publication 20230085986A1 · Mar 23, 2023